Abstract
Ankylosing Spondylitis (AS) is a chronic inflammatory disease that can lead to severe complications such as femoral head necrosis (FHN). This study aimed to identify the molecular drivers of AS-related FHN by integrating tissue proteomics, bioinformatics, and clinical validation. The findings highlight SAA1, TUBA8, and monocytes as critical factors in the pathogenesis of this condition, offering potential biomarkers and therapeutic targets.
Introduction
Ankylosing Spondylitis primarily affects the axial skeleton, but its involvement in the hip joint—specifically leading to femoral head necrosis—significantly increases patient morbidity. Despite its clinical importance, the molecular mechanisms driving AS-related FHN remain poorly understood. This study sought to bridge this knowledge gap by identifying specific genetic and immune dysregulations within the hip ligaments of affected patients.
Methodology
The researchers employed a multi-omic systems biology approach:
- Proteomics: Label-free quantification (LFQ) was used to analyze ligament tissues from 12 patients (6 with AS+FHN and 6 with FHN only) to identify differentially expressed proteins (DEPs).
- Network Analysis: Weighted Gene Co-expression Network Analysis (WGCNA) identified protein modules most highly correlated with the disease state.
- Intersection Analysis: Hub genes were identified by finding the overlap between DEPs, relevant WGCNA modules, and hypoxia-related gene sets.
- Immune Profiling: The CIBERSORT algorithm estimated immune cell proportions, which were then validated against clinical blood data from a cohort of 502 AS patients and 162 healthy controls.
Results
Identification of Hub Genes
The "triple intersection" strategy pinpointed SAA1 (Serum Amyloid A1) and TUBA8 (Tubulin Alpha 8) as the primary hub genes. These proteins are central to the hypoxia-inflammation axis that characterizes AS-related FHN.
Immune Landscape and Clinical Validation
Bioinformatic analysis revealed significant correlations between the identified hub genes and specific immune cell types. SAA1 showed a strong positive correlation with resting mast cells ($R = 0.85, P < 0.001$) and a negative correlation with M0 macrophages ($R = -0.67, P = 0.016$).
Clinical validation confirmed that monocytes were significantly elevated in AS patients compared to healthy controls ($P < 0.05$), while eosinophil counts were lower. This suggests that monocytes play a key role in the systemic inflammatory environment contributing to hip joint damage.
Therapeutic Insights
Correlation analysis with the CellMiner database suggested that SAA1 and TUBA8 expression levels might predict sensitivity to certain drugs, including methotrexate and tamoxifen, paving the way for personalized treatment approaches.
Discussion
This study identifies a specific molecular signature—comprising SAA1, TUBA8, and monocytes—that drives the progression of femoral head necrosis in AS patients. The link between these genes and hypoxia underscores the complex nature of the disease. While the initial proteomic sample size was limited, the large-scale clinical validation of immune markers provides strong support for the findings. Future functional studies are required to confirm the causative roles of these proteins and their potential as therapeutic targets.
Conclusion
Dysregulation of SAA1, TUBA8, and monocytes are key factors in AS-related femoral head necrosis. These findings provide a foundation for developing early diagnostic biomarkers and targeted immunotherapies to prevent debilitating hip complications in AS patients.
Summary updated